Signals
Down Syndrome Cannot Stay Outside Alzheimer’s Trials
Alnylam has launched a Phase 2 study of mivelsiran in Down syndrome-associated Alzheimer’s disease. The trial is early, but the access issue is already mature: a high-risk population cannot remain peripheral to Alzheimer’s research.
AI Eye Screening Has an Image Quality Problem
AI Retinal Screening Moves Into the Diabetes Clinic
India Turns AI Eye Screening Into Public-Health Infrastructure
Africa’s Cardiovascular Decade Is a System-Design Problem
Inherited Lipid Screening Becomes Europe’s Prevention Test
ATTR Gene Editing Restarts, But Safety Becomes the Access Question
Routine CT Scans Could Become a Heart Failure Early-Warning System
Risk Prediction Cannot Simply Be Imported From Europe
Personalised Cardiology Needs a Digital Fabric, Not Just More Data
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.